RESUMEN
Firmly bound IgG was examined and its activity was tested in spontaneous lung carcinoma of sheep (jaagsiekte). High levels of IgG were extracted by acid-glycine buffer (GB) at pH 2.8 from both the tumor tissue and normal lung, which were exhaustively prewashed by phosphate-buffered saline (PBS) at pH 7.4. The first acid-GB eluates of the normal or tumor tissue acted in the immunodiffusion test as precipitating antibodies against antigens of the first PBS eluate of the tumor tissue. In addition, free intracytoplasmic type A particles were observed in cell-free tumor extract.
Asunto(s)
Anticuerpos/aislamiento & purificación , Adenomatosis Pulmonar Ovina/inmunología , Animales , Especificidad de Anticuerpos , Inmunoglobulina G , Cuerpos de Inclusión Viral , Pulmón/inmunología , Adenomatosis Pulmonar Ovina/patología , OvinosRESUMEN
Serum antibodies to the reverse transcriptase (ART) of human immunodeficiency virus 1 (HIV-1) were sequentially determined by ELISA in a group of 41 HIV-seropositive male homosexuals and 101 matched healthy controls, over 1.5-6 years (mean follow-up 3.25 years). Mean ART levels were significantly higher in the patient group as compared to the controls (195 +/- 75 vs. 75 +/- 45 absorbance (A) units; P less than 0.05). When analyzed in parallel with clinical evaluation and T-cell subset determinations, a "surge" in ART activity was associated with a more favourable course: eleven patients whose ART profile showed an increase greater than 100 A units (mean delta A 159.6 units) showed an attenuated decrease of CD4+ (T helper) lymphocytes with a mean time of 42.5 months to reach a CD4+ number of 400 cells/mm3. In contrast, 25 matched seropositive patients whose ART remained constant became CD4+ less than 400 cells/mm3 within a mean time of 10.8 months (P less than 0.05). These results as well as individual patients' data support a surge in serum ART as a favourable prognostic indicator, and may indicate a protective role for this antibody which should be followed up and possibly utilized in the treatment or in the design of a vaccine against HIV-1.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/inmunología , Anticuerpos Anti-VIH/inmunología , Infecciones por VIH/inmunología , VIH-1/inmunología , ADN Polimerasa Dirigida por ARN/inmunología , Síndrome de Inmunodeficiencia Adquirida/patología , Relación CD4-CD8 , Linfocitos T CD4-Positivos/inmunología , Ensayo de Inmunoadsorción Enzimática , Transcriptasa Inversa del VIH , Seropositividad para VIH/inmunología , VIH-1/enzimología , Humanos , Masculino , Linfocitos T Reguladores/inmunologíaRESUMEN
The feasibility of using Thymic Humoral Factor (THF) for immunomodulation in asymptomatic male homosexuals was evaluated in a study on fifteen subjects with T-cell impairments, selected on the basis of a 2SD reduction in T helper/inducer (T4+) cells and one additional lymphocytic defect. Following two biweekly courses of treatment, mean relative increments of T4+ (P less than 0.002), T3+ (P less than 0.02) and total lymphocyte (P less than 0.05) populations of the group receiving THF (n = 7) were significantly increased when compared to the placebo group (n = 8). In addition, a transient increase in T4+ lymphocytes was observed after the first course in the two individuals of the THF-treated group who were seropositive for HTLV-III/LAV but not in those who were seronegative. No difference was found between the groups in fluctuations of serum interferon (IFN) or proliferation of peripheral mononuclear cells to mitogens. The results of this limited trial demonstrate that THF is capable of correcting T-cell impairments that may predispose asymptomatic homosexuals to infection by HTLV-III, without affecting IFN production. These findings suggest that future strategies for AIDS prevention in high-risk groups should include institution of large controlled trials in immunodeficient, asymptomatic, HTLV-III/LAV-seronegative male homosexuals to study the potential of selective immunoreconstitution as a preventive measure against HTLV-III/LAV infection.